Status: 08/01/2021 11:34 a.m.
BioNTech has grown strongly since the beginning of the pandemic. Now the Mainz biotechnology company has advertised numerous other positions “across all departments”. The focus is on sales.
The Mainz corona vaccine manufacturer BioNTech is expanding. An extensive job creation is planned for the coming months, the company said, according to a report by “Welt am Sonntag”. 500 new positions across all departments are currently advertised. Before the corona pandemic, BioNTech employed a good 1,300 people.
The company worked primarily on new therapies for cancer. Together with the US company Pfizer, BioNTech then developed the first vaccine against the coronavirus approved in many countries last year. To do this, the company used the new mRNA technology, which is also used in the development of cancer immunotherapies. BioNTech recently announced that it wanted to develop a malaria vaccine.
Number of employees has grown in pandemic
In the past year and a half, the number of BioNTech employees has already risen to around 2000. According to the “Welt am Sonntag” report, the manufacturer now wants to invest in its own sales team of 60 employees for the first time in order to promote the marketing of approved products itself.
“We set up BioNTech as a fully integrated company from the start. With our own research and development, production and now also sales,” said board member Sierk Poetting of the newspaper.